A new drug in clinical trials is showing promise in lowering a key genetic risk factor for heart attacks and ...

A single dose of an siRNA molecule reduces elevated lipoprotein(a) — a major, but to date, largely untreatable risk factor ...

About a quarter of people risk heart attacks and strokes because they inherited a kind of cholesterol that statin drugs can’t ...

A new drug called lepodisiran may offer hope to millions of people at risk of heart attacks and strokes by targeting a little ...

Diabetes patients on dulaglutide (Trulicity) had better glycemic control and more weight loss if they switched to tirzepatide ...

The study finds better A1c lowering and weight reduction, but an expert clinician says practical issues may pose barriers.

A dose of an experimental drug reduced the levels of a fatal type of cholesterol for up to a year despite previous knowledge that it's untreatable. NBC News reported that pharmaceutical company Eli ...

Eli Lilly focuses on genetic medicine, developing treatments for diabetes, heart disease, deafness, Parkinson's, and Alzheimer's. Expanding in India.

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

Even statins don’t work on risk factor called lipoprotein (a) that quickly clings to arteries and narrows them ...

Patients at risk for heart disease experienced significant reductions in apolipoprotein B and LDL cholesterol levels on ...

Eli Lilly rolled out positive Phase 2 results for lepodisiran, a therapy targeting lipoprotein(a)—that genetic party crasher ...